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17b-Estradiol (E2) induces cathepsin D mRNA levels and intracellular levels of immunoreactive protein in
MCF-7 human breast cancer cells. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alone does not affect cathepsin
D gene expression in this cell line; however, in cells cotreated with TCDD and E2, TCDD inhibited E2-induced
cathepsin D mRNA levels, the rate of gene transcription, and levels of immunoreactive protein. The inhibitory
responses were observed within 30 to 120 min after the cells were treated with TCDD. TCDD also inhibited
E2-induced secreted alkaline phosphatase activity in aryl hydrocarbon (Ah)-responsive MCF-7 and wild-type
mouse Hepa 1c1c7 cells cotransfected with the human estrogen receptor (hER) and the pBC12/S1/pac plasmid,
which contains the 5* promoter region (2296/157) of the cathepsin D gene and an alkaline phosphatase
reporter gene. The E2-responsive ER/Sp1 sequence (2199 to 2165) in the cathepsin D 5* region contains an
imperfect GTGCGTG (2175/2181) xenobiotic responsive element (XRE); the role of this sequence in Ah
responsiveness was investigated in gel electrophoretic mobility shift assays and with plasmid constructs
containing a wild-type ER/Sp1 oligonucleotide or a mutant ER/Sp1-‘‘XRE’’ oligonucleotide containing two
C3A mutations in the XRE sequence (antisense strand). In plasmid constructs which contained a chloram-
phenicol acetyltransferase reporter gene and the wild-type ER/Sp1 promoter sequence, E2-induced chloram-
phenicol acetyltransferase activity and mRNA levels were inhibited by TCDD whereas no inhibition was
observed with the mutant ER/Sp1-‘‘XRE’’ plasmids. Electrophoretic mobility shift assays showed that the
nuclear or transformed cytosolic Ah receptor complex blocked formation of the ER-Sp1 complex with the
wild-type but not the ER/Sp1 mutant oligonucleotide. Moreover, incubation of the wild-type bromodeoxyuri-
dine-substituted ER/Sp1 oligonucleotide with the nuclear Ah receptor complex gave a specifically bound
cross-linked 200-kDa band. These data demonstrate that Ah receptor-mediated inhibition of E2-induced
cathepsin D gene expression is due to disruption of the ER-Sp1 complex by targeted interaction with an over-
lapping XRE.
The aryl hydrocarbon (Ah) receptor protein is expressed in
laboratory animals and humans and in mammalian cells in
culture (54, 65). Although the endogenous ligand(s) for this
receptor has not been identified, several different classes of
compounds reversibly bind the Ah receptor, and these include
the polynuclear and polyhalogenated aromatic hydrocarbons
(42, 54, 57, 59, 65, 67). 3-Methylcholanthrene and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) are prototypical aro-
matic hydrocarbons which exhibit high-affinity binding (Kd # 1
nM) for the Ah receptor (44, 58) and have been utilized for
characterizing Ah receptor-mediated responses.
TCDD induces a broad spectrum of biochemical and toxic
responses including a wasting syndrome, immune suppression,
hepatotoxicity, developmental and reproductive toxicity, carci-
nogenicity, dermal toxicity, alteration of endocrine response
pathways, and modulation of diverse enzyme activities (26, 29,
59, 73, 82). The induction of CYP1A1 gene expression by
TCDD and 3-methylcholanthrene has been extensively inves-
tigated, and the results indicate that the Ah receptor acts as a
nuclear ligand-induced transcription factor (13, 29, 73, 82).
After treatment of animals or cells with TCDD, there is a rapid
formation of a heterodimeric nuclear Ah receptor complex
(19) which consists of the ligand-binding protein (7) and the
Ah receptor nuclear translocator (Arnt) protein (31). The un-
bound Ah receptor is associated with heat shock protein 90
(48, 55, 60, 61), and the subcellular distribution of these pro-
teins in the absence of ligand is currently being investigated
(60, 61). The nuclear Ah receptor complex interacts with cog-
nate genomic sequences (dioxin or xenobiotic responsive ele-
ments [DREs and XREs, respectively]) in the 59-promoter
region of the CYP1A1 gene and transactivates CYP1A1 gene
expression (15–17, 27, 34, 70, 83). There is evidence that this
transactivation process is comparable for induction of CYP1A1
gene expression and induction of the expression of other mem-
bers of the Ah gene battery, namely CYP1A2, glucuronosyl
transferase, aldehyde-3-dehydrogenase, glutathione S-trans-
ferase Ya gene, and NAD(P)H:menadione oxidoreductase (1,
35, 53, 56, 62, 64). Other studies also report that enhanced
expression of other genes by TCDD is due to posttranscrip-
tional processes (20).
TCDD also decreases gene expression and/or the respective
activities of the encoded proteins. Phosphoenolpyruvate car-
boxy kinase, glucose-6-phosphatase, and tryptophan 2,3-dioxy-
genase activities and mRNA levels are decreased in rats
treated with an acutely toxic dose (125 mg/kg of body weight)
of TCDD (72). Rat uterine c-fos and epidermal growth factor
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receptor mRNA levels are also decreased (2, 3), and decreased
epidermal growth factor receptor mRNA levels or binding
activity has been observed in several animal species and mam-
malian cells (33, 36, 43). TCDD inhibits several estrogen (E2)-
induced responses in the rodent uterus (21, 66) and mammary
gland including the development and formation of mammary
tumors in female Sprague-Dawley rats and B6D2 mice (22, 32,
38). The antiestrogenic effects of TCDD and related com-
pounds have also been reported in Ah-responsive MCF-7 hu-
man breast cancer cells (22–25, 30, 40). TCDD and related
compounds inhibit E2-induced cell proliferation, progesterone
receptor protein and mRNA levels, postconfluent focus pro-
duction and extracellular tissue plasminogen activator activity,
procathepsin D, and cathepsin D. This study will utilize the
E2-regulated cathepsin D gene as a model for investigating the
mechanism of action of TCDD as an antiestrogen.
Cathepsin D is expressed in human mammary cancer cells
and tumors, and levels of this protein are used as a negative
prognostic indicator for disease-free survival for women with
breast cancer (71, 74, 75). Treatment of MCF-7 cells with E2
results in the induction of cathepsin D gene expression and
increased intra- and extracellular levels of procathepsin D and
cathepsin D (8–11, 47, 52, 76, 79–81). Cavailles et al. (10) have
reported that cathepsin D gene transcription is initiated at five
start sites (I to V); E2 induces transcription from start site I,
and this response is dependent on an intact TATA sequence
between 240 to 244. The 59-proximal flanking region of the
cathepsin D gene does not contain a classical palindromic
estrogen-responsive element (ERE); however, deletion analy-
sis experiments show that a promoter fragment from 2365 to
2122 was required for E2 responsiveness (4, 9, 10). More
recent data confirmed the importance of this sequence and
suggested that E2 regulation of this promoter sequence was
complex and appeared to require cooperative interactions with
other trans-acting nuclear factors such as Sp1 (4). An imperfect
ERE half-site and an Sp1 binding site were identified in the
cathepsin D promoter between 2199 to 2165 (41), and this
site was protected in DNase I footprinting assays using E2-
induced nuclear extracts (4). Research in this laboratory
showed that incubation of nuclear extracts from E2-treated
MCF-7 cells with a synthetic [32P]ER/Sp1 oligonucleotide
(2199 to 2165) resulted in formation of an ER-Sp1 complex
which could be detected by gel electrophoretic mobility shift
assays. Subsequent studies with wild-type and mutant ER/Sp1
oligonucleotides in electrophoretic mobility shift and transient
transfection assays showed that formation of an ER-Sp1 com-
plex was required for the E2-induced response (41). The re-
sults reported in this study demonstrate that TCDD inhibits
E2-induced cathepsin D gene expression and chloramphenicol
acetyltransferase (CAT) activity in MCF-7 cells transiently
transfected with an ER/Sp1-tk-CAT construct. The data indi-
cate that the inhibitory effects of TCDD are associated with
direct interaction of the nuclear Ah receptor complex with an
XRE strategically located between the ER and Sp1 response
elements. Thus, the nuclear Ah receptor complex acts as a
negative transcriptional factor, and the results illustrate a mo-
lecular model for interaction between the Ah receptor- and
ER-mediated endocrine pathways.
MATERIALS AND METHODS
Chemicals, biochemicals, cells, oligonucleotides, and plasmids. TCDD,
[3H]TCDD (32 Ci/mmol), and 2,3,7,8-tetrachlorodibenzofuran (TCDF) were
synthesized in this laboratory (.98%). RPMI 1640, DME-F12 (2906), controlled
processed serum replacement (CPSR-2), transferrin, bovine serum albumin,
antibiotic-antimycotic solution, and E2 were purchased from Sigma Chemical
Co. (St. Louis, Mo.). Fetal calf serum was obtained from JRH Biosciences
(Kansas City, Mo.). An ELSA cath-D radioimmunoassay (RIA) kit was pur-
chased from CIS-US Inc. (Bedford, Mass.). a-Naphthoflavone (aNF) was pur-
chased from the Aldrich Chemical Co. (Milwaukee, Wis.). [g-32P]ATP (3,000
Ci/mmol), [3H]17b-estradiol (130 Ci/mmol), and [a-32P]UTP (800 Ci/mmol)
were obtained from New England Nuclear (Boston, Mass.). All other chemicals
and biochemicals were of the highest purity available from commercial sources.
The human estrogen receptor (hER) expression plasmid was provided by
Ming-Jer Tsai (Baylor College of Medicine, Houston, Tex.). The pB12/pL/pac
(Seap-pac) plasmid containing the cathepsin D promoter (2296/157) fused to
an alkaline phosphatase gene was used to study the promoter activity (63). The
pBC12/S1/pac (S1) plasmid containing no promoter and the pBC12/RSV/pac
(RSV) plasmid containing a Rous sarcoma virus promoter fused to the alkaline
phosphatase gene were used as negative and positive controls, respectively. The
above plasmids were generous gifts from Andrej Hasilik, Mu¨nster, Germany
(with permission from B. R. Cullen, Duke University, Durham, N.C.). A 2.6-kb
BamHI fragment containing the entire arnt cDNA was isolated from the pMB5/
NEO-M1-1 expression vector (kindly supplied by O. Hankinson, University of
California at Los Angeles) and religated in the pcDNA1/NEO expression vector
(Invitrogen). The direction of the arnt cDNA was confirmed by PvuII restriction
mapping. The correct bacterial clone was amplified, and the plasmid containing
antisense arnt cDNA was purified and used in the experiment. The MCF-7 cells
were purchased from the American Type Culture Collection (Rockville, Md.);
the wild-type and class II mutant Hepa 1c1c7 cells were kindly provided by J. P.
Whitlock, Jr. (Stanford University). This mutant cell line expresses the cytosolic
Ah receptor, but TCDD does not induce formation of the nuclear Ah receptor
complex (50).
The ER/Sp1 and ER/Sp1-‘‘XRE’’ oligonucleotides were synthesized by DNA
Technologies Laboratory, Texas A&M University. The complementary strands
were annealed, and the 59 overhangs were used for cloning into the thymidine
kinase-CAT vector (37). Ligation products were transformed into Escherichia
coli DH5a cells, and clones obtained were verified by restriction mapping. Plas-
mids containing cDNA probes for Northern (RNA) analysis of cathepsin D and
b-tubulin mRNA levels were obtained from the American Type Culture Collec-
tion. A cDNA for CAT mRNA was kindly provided by D. O. Peterson (Texas
A&M University). Quantitation of radiolabeled bands after separation by elec-
trophoretic and chromatographic assays was determined with a Betagen Betas-
cope 603 blot analyzer. The following oligonucleotides were synthesized and
used in this study: ER/Sp1 oligonucleotide (antisense strand), 59-GATCCTGGG
CGGGGCAACCTCGGGCACGCACAGCGCCCGGGCGGGGGGCGGG
GA-39; ER/Sp1-‘‘XRE’’ oligonucleotide (antisense strand), 59-GATCCTGGGC
GGGGCAACCTCGGGCAAGAACAGCGCCCGGGCGGGGGGCGGGGA-39;
DRE, 59-GATCTGGCTCTTCTCACGCAACTCCG-39; DRE9 (mutant), 59-GA
TCCCAGGCTCTTCTACATCAACTCCGGGGC-39; and cross-linking primer
sequence, TCCCCGCCCCCCGCC.
RIA for cathepsin D. The commercially available ELSA cath-D kit consisted of
ELSA tubes coated with the anti-cathepsin-D monoclonal antibody (8, 39); 300
ml of monoclonal 125I-labeled anti-cathepsin-D antibody and then 50 ml of
sample (medium or cytosolic extract) were added to each tube. This mixture was
then incubated at 258C with shaking in an incubator shaker for 3 h. The tubes
were then washed three times with 3 ml of Tween 20 solution after the contents
in the tube were removed by aspiration. The tubes were then measured for
bound 125I in a Packard gamma scintillation counter. Quantitation of cathepsin
D in the samples was based on a standard curve obtained as outlined in the
instructions provided in the kit.
Northern blot analysis of cathepsin D mRNA. Cathepsin D mRNA levels were
measured by using a 1.2-kb EcoRI fragment of the human cathepsin D cDNA.
b-Tubulin mRNA levels were measured by using a 1.1-kb EcoRI fragment of
human b-tubulin cDNA. Total RNA was isolated by the guanidinium isothio-
cyanate-acid phenol extraction method (12). Total RNA (20 mg) was separated
in a 1.2% agarose–1 M formaldehyde gel in 20 mM sodium phosphate–2 mM
EDTA, transferred onto a nylon membrane by capillary action, and bound to the
membrane by UV cross-linking. The cDNAs were labeled with [a-32P]dCTP by
using a Random Primers DNA labeling system (Bethesda Research Laborato-
ries) and added at 13 106 to 53 106 cpm/ml of hybridization solution (53 SSPE
[13 SSPE is 0.15 M NaCl, 10 mM NaH2PO4, 1 mM EDTA; pH 7.4], 1% sodium
dodecyl sulfate [SDS], 10% dextran sulfate, 53 Denhardt’s solution). Hybrid-
izations were performed in roller bottles at 658C for 24 h. Nonspecifically-bound
probe was removed by two 15-min washes at 208C in 13 SSPE, two 45-min
washes at 658C in 0.13 SSPE–1% SDS, and one 20-min wash at 208C in 13
SSPE. Membranes were stripped of probe by boiling for 20 min in 0.013 SSPE–
0.5% SDS. Bands were quantitated with a Betagen Betascope 603 blot analyzer
imaging system. Four separate experiments were carried out for each treatment
group, and the results are expressed as means 6 standard deviations (SD).
Nuclear run-on assays.MCF-7 cells (5 3 107) were harvested, resuspended in
5 ml of 1.5 M sucrose buffer plus 0.1% Brij 58, and homogenized with 10 to 20
strokes in a Dounce homogenizer. The homogenate was diluted to 15 ml with 1.5
M sucrose and centrifuged at 10,000 rpm for 20 min at 48C. The nuclear pellet
was resuspended in 0.5 ml of nucleus storage buffer (20 mM HEPES [N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid; pH 8.3], 75 mM NaCl, 0.5 mM
EDTA, 0.85 mM dithiothreitol, 0.125 mM phenylmethylsulfonyl fluoride, 50%
glycerol). The concentration of nuclei was determined by diluting an aliquot in
0.5% (wt/vol) trypan blue and counting with a hemocytometer. Aliquots of 2 3
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106 nuclei were then stored in liquid nitrogen until the transcription elongation
assay was performed. The nuclear transcription run-on assay was performed
essentially as described elsewhere (45). Briefly, nuclei were isolated at the ap-
propriate times after treatment with TCDD and incubated with [a-32P]UTP (200
mCi) and unlabeled ATP, CTP, and GTP (0.5 mM for each nucleotide). The
radiolabeled RNA transcripts were isolated and hybridized to excess (10 mg) of
denatured cDNA immobilized onto a nylon membrane by using a slot blot
apparatus (Hoefer PR600). The membranes were exposed for 5 weeks, visualized
by autoradiography, and quantitated by a Molecular Dynamics 300A scanning
laser densitometer.
Preparation and transformation of cytosolic extracts.MCF-7 cells were grown
in DME-F12 medium supplemented with 10% fetal bovine serum (23 dextran-
coated charcoal). Cells were harvested and washed with Hanks solution. Cells
were washed in HEDG buffer (25 mM HEPES, 1.5 mM EDTA, 1 mM dithio-
threitol, 10% glycerol [pH 7.6]) and incubated in HED buffer (HEDG buffer
without glycerol) for 10 min at 48C. The cells were then centrifuged at 800 3 g
for 10 min, followed by homogenization using a Teflon pestle-drill apparatus in
1 ml of HEDG buffer. The cell suspension was centrifuged at 1,000 3 g for 10
min at 48C. The supernatant was subjected to ultracentrifugation at 4,0003 g for
30 min at 48C. Supernatant was obtained and protein content was quantitated by
the Bradford assay (6). Cytosolic extract (1 mg of protein per ml) was incubated
with 20 nM TCDD for 2 h at 258C. Transformed cytosol (100 ml) was incubated
with nuclear extracts from MCF-7 cells and analyzed by electrophoretic mobility
shift assays using ER/Sp1 and ER/Sp1-‘‘XRE’’ oligonucleotides.
Electrophoretic mobility shift assays. Complementary strands of the synthetic
ER/Sp1 and mutated ER/Sp1-‘‘XRE’’ oligonucleotides were labeled at the 59 end
by using T4 polynucleotide kinase and [g-32P]ATP (68). Nuclear extracts (5 mg)
from MCF-7 and HeLa cells treated with dimethyl sulfoxide (DMSO) (,0.1%)
and other appropriate chemicals were incubated in TEGD buffer with 1 mg of
poly(dI-dC) for 15 min at 208C to bind nonspecific DNA-binding proteins.
Following addition of 1 nM 32P-labeled specific oligonucleotide, the mixture was
incubated for 15 min at 208C. For competition with specific unlabeled oligonu-
cleotides, the unlabeled oligonucleotide in appropriate excess was incubated for
5 min prior to the addition of the labeled oligonucleotide. Reaction mixtures
were loaded onto a 5% polyacrylamide gel (acrylamide/bisacrylamide ratio, 30:
0.8) and run at 110 V in 0.09 M Tris–0.09 M borate–2 mM EDTA, pH 8.3. The
relative intensities of the retarded complexes were quantitated by the Betagen
Betascope 603 blot analyzer imaging system, visualized by autoradiography, and
also quantitated with a model 300A scanning laser densitometer (Molecular
Dynamics).
Cloning, transient transfection, CAT, and alkaline phosphatase assays. Clon-
ing of the ER/Sp1 and the mutant ER/Sp1-‘‘XRE’’ oligonucleotides into the
thymidine kinase-CAT vector at the BamHI and HindIII sites was carried out as
previously described (37, 41). Transient transfection of the CAT plasmids and
the Seap-pac, S1, RSV, and hER plasmids was carried out essentially as de-
scribed elsewhere (37, 41). MCF-7 cells were cotransfected with a Polybrene
(200-mg/ml) solution containing 5 to 20 mg of appropriate plasmid DNA and the
hER plasmid. After 6 h, the cells were shocked with 15% glycerol in Hanks
solution for 75 s, washed twice with the same solution, and grown in DME-F12
(without phenol red)–5% stripped fetal bovine serum. Cells were dosed 12 h
after being shocked with appropriate chemicals dissolved in DMSO; control cells
were treated with DMSO alone (,0.1%). Two days later the cells were removed
by manual scraping, cell extracts were obtained, and 100 mg of protein extract
was used to determine CAT activity as previously described (28, 37). Levels of
acetylated product were quantitated by a Betagen Betascope 603 blot analyzer
imaging system and visualized by autoradiography. Secreted alkaline phos-
phatase activity was determined essentially as described elsewhere (5, 63). One
milliliter of medium was obtained at the appropriate times and incubated for 10
min at 658C. The medium was then centrifuged at 10,000 3 g for 5 min, and 900
ml of the supernatant was mixed with an equal amount of Seap buffer (5). This
mixture was then warmed in a 378C water bath separately, along with freshly
prepared substrate (120 mM p-nitrophenyl phosphate). The two solutions were
mixed with constant vortexing and incubated in the 378C water bath for 6 h. The
product of the alkaline phosphatase reaction was quantitated with a spectropho-
tometer at an optical density at 405 nM. The activity from each sample was
compared with the standard curve obtained by using a serial dilution of alkaline
phosphatase enzyme activity (5).
Cross-linking studies. For cross-linking studies, 10 pmol of the synthetic oli-
gonucleotide ER/Sp1 was annealed to 10 pmol of a cross-linked primer se-
quence. The annealed template was end filled with the Klenow fragment of DNA
polymerase in the presence of 0.1 mM dGTP, dATP, and bromodeoxyuridine
(BrdU) and 1 mM [32P]dCTP (68) and was designated the BrdU-substituted
DRE oligonucleotide. Nuclear extracts (10 mg) from MCF-7 cells treated with
appropriate chemicals (i.e., E2, E2 plus TCDD, or [3H]TCDD) were incubated
with the BrdU-substituted 32P-labeled DRE for 15 min at 208C following a
15-min incubation at 208C with 400 ng of poly(dI-dC) in HEGD buffer or for 10
min followed by a 5-min incubation at 208C with unlabeled excess competitor.
The incubation mixtures were irradiated by using a FOTODYNE UV transillu-
minator at .205 nm for 30 min at 208C. Samples were then mixed with 20 ml of
an SDS loading buffer, heated to 958C for 5 min, and then subjected to electro-
phoresis on SDS–6% polyacrylamide gels. 32P-labeled ligand-Ah receptor-DRE
complexes were resolved by autoradiography of the dried gel. When 10 nM
[3H]TCDD (62 mM TCDF) was used in the experiments, the resulting gels were
cut into eight (1.2-cm) slices and extracted with Solvable (Dupont, Boston,
Mass.) and radioactivity was determined by liquid scintillation counting. Molec-
ular weights of UV cross-linked nuclear and transformed ligand-Ah receptor-
ER/Sp1 complexes were calculated from 14C-methylated protein standards ob-
tained from Amersham Corp. (Arlington Heights, Ill.).
Electrophoretic mobility shift assays using in vitro-translated proteins. Plas-
mids containing the full-length Ah receptor and Arnt cDNAs were used to in
vitro transcribe and translate the corresponding proteins in a rabbit reticulocyte
lysate kit (Promega, Madison, Wis.). DNA binding assays were performed by
assembling the appropriate in vitro-translated proteins in 20 mM HEPES–5%
glycerol–100 mM potassium chloride–5 mMmagnesium chloride–0.5 mM dithio-
threitol–1 mM ethylene diaminetetraacetic acid in a final volume of 25 ml. The
labeled oligonucleotides (30,000 cpm) were then added to the reaction mixtures
in the presence of 1 mg of poly(dI-dC), and the mixtures were incubated for 15
min at 258C. Reaction mixtures were immediately analyzed by gel electrophoretic
mobility shift assays as described above. Gels were dried, and protein-DNA
binding was visualized by autoradiography.
Statistical analysis. All the experiments were carried out at least in triplicate,
and the results were expressed as means 6 SD. Statistical significance was
determined by analysis of variance using Scheffe’s post hoc test.
RESULTS
Effects of TCDD on E2-induced cytosolic immunoreactive
cathepsin D.MCF-7 cells were treated with 1 nM E2 alone for
24 h; cotreated cells were also treated with 1 nM E2 for 24 h,
and 1 nM TCDD was added 2, 4, 6, and 12 h prior to harvesting
of the cells and isolation of cytosolic extracts. Extracts were
analyzed for immunoreactive cathepsin D by using a commer-
cially available RIA kit to detect and quantitate intracellular
levels of cathepsin D as previously described (39). The results
in Fig. 1 (top) illustrate that E2 alone induced cathepsin D
levels (1.8-fold); TCDD alone also slightly increased levels of
this protein compared with control (DMSO-treated) cells. In
cells cotreated with 1 nM E2 for 24 h and TCDD for 2, 4, 6, or
12 h, there was a significant decrease in immunoreactive ca-
thepsin D at the earliest time point.
Effects of TCDD on E2-induced cathepsin D mRNA levels
and rate of transcription. The results in Fig. 1 summarize the
time-dependent decrease in E2-induced cathepsin D mRNA
levels by TCDD. Treatment of MCF-7 cells for 24 h with 10
nM E2 resulted in a threefold increase in cathepsin D mRNA
levels. In cells cotreated with 10 nM E2 for 24 h and 10 nM
TCDD for 1, 2, 4, 8, or 12 h, there was significant decrease in
cathepsin D mRNA levels at the earliest time point. TCDD
alone caused some initial increase in cathepsin D mRNA lev-
els. The results in Fig. 2 summarize the effects of E2 and
TCDD plus E2 on the rate of cathepsin D gene transcription in
nuclear run-on assays. E2 caused a 6.8-fold increase in cathep-
sin D mRNA levels, whereas in cells cotreated with E2 plus
TCDD a significant decrease in E2-induced mRNA levels was
observed 30 or 60 min after addition of TCDD. A Northern
blot of cathepsin D mRNA levels after treatment with DMSO,
E2, or TCDD plus E2 is shown in Fig. 2C. These data dem-
onstrate the E2 inducibility of cathepsin D gene expression as
previously reported (11, 41, 47, 76, 80). Moreover, like ICI
164,384, an antiestrogen which blocks formation of the ER
homodimer (14), TCDD also inhibits E2-induced cathepsin D
gene expression. However, the inhibitory effects of TCDD in
the nuclear run-on assay were observed within 30 min (Fig. 2),
whereas the effects of ICI 164,384 occurred 2 to 4 h after
treatment (41).
Inhibition of E2-induced cathepsin D promoter activity in
MCF-7, wild-type, and mutant mouse Hepa 1c1c7 cells. The
effects of TCDD on cathepsin D promoter activity were deter-
mined in MCF-7 human breast cancer cells and wild-type and
mutant mouse Hepa 1c1c7 cells cotransfected with the Seap-
pac and hER plasmids and treated with E2, TCDD, or E2 plus
TCDD (Table 1). Because of the relatively high expression of
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the recombinant plasmid, cotransfection of the hER expres-
sion plasmid was required for E2 responsiveness. Cotransfec-
tion of the hER plasmid has previously been reported with
plasmid constructs derived from 59-promoter sequences of the
cathepsin D, pS2, and progesterone receptor genes (9, 10, 41,
69, 85). In MCF-7, wild-type, and mutant Hepa 1c1c7 cells
cotransfected with the Seap-pac and hER plasmids, 10 nM E2
induced an 8.4-, a 6.9-, and a 6.4-fold increases in secreted
alkaline phosphatase activity, respectively. For cells cotreated
with 10 nM E2 for 48 h plus 10 nM TCDD for different
periods, TCDD caused a time-dependent decrease in secreted
alkaline phosphatase activity in MCF-7 and wild-type Hepa
1c1c7 cells whereas no inhibitory effects were observed in class
II mutant Hepa 1c1c7 cells. In MCF-7 cells treated with 10 nM
TCDD alone and transfected with the Seap-pac plasmid, alka-
line phosphatase activity was not significantly induced. Ten
nanomolar TCDD was the optimum concentration for inhibi-
tion of E2-induced activity in all the transient transfection
studies, and this concentration was not cytotoxic or growth
inhibitory. Ten nanomolar E2 was also the optimal concentra-
tion which was used in all the transient transfection studies.
CAT assays and CAT mRNA levels. An ER/Sp1 sequence in
the cathepsin D promoter (2199 to 2165) has been cloned
into a thymidine kinase-CAT plasmid (41), and the effects of
E2, TCDD, and E2 plus TCDD on CAT activity in MCF-7 cells
transiently cotransfected with this plasmid and the hER plas-
mid were determined (Fig. 3). The results show that E2 in-
duced CAT activity (lane 2) and TCDD inhibited the E2-
induced response (lane 3). In addition, cotreatment of MCF-7
cells with aNF (lanes 5 and 6), an Ah receptor antagonist, or
cotransfection with a plasmid expressing antisense Arnt (lanes
7 through 10) resulted in reversal of the TCDD-mediated
decrease in E2-induced CAT activity (lanes 5 and 9, respec-
tively). TCDD inhibits E2-induced ER/Sp1 binding (lanes 2
and 3), and aNF reverses this inhibitory effect (lane 5). A
plasmid containing mutations in the XRE (ER/Sp1-‘‘XRE’’-tk-
CAT) was utilized to determine the role of this sequence in
mediating the effects of TCDD (lanes 11 through 14). E2
induced CAT activity in the transient transfection assay using
the mutant ER/Sp1-‘‘XRE’’-tk-CAT plasmid (lane 12), but
TCDD did not significantly inhibit E2-induced CAT activity
(lane 13) with this plasmid. These results show that the mutant
ER/Sp1-‘‘XRE’’-tk-CAT plasmid retains E2 responsiveness;
however, TCDD did not inhibit E2-induced CAT activity.
These data indicate that an intact XRE is required for TCDD
responsiveness.
In parallel experiments with MCF-7 cells, the effects of 10
nM TCDD on E2-induced CAT mRNA levels were also de-
termined by Northern blot analysis (Table 2). The cells were
treated with 10 nM E2 for 24 h and 10 nM TCDD for 2 h. The
results show that in cells transiently transfected with the wild-
type ER/Sp1-tk-CAT plasmid, E2 induced CAT mRNA levels
and TCDD inhibited the E2-induced response. E2 also in-
duced CAT activity in cells transiently transfected with the
mutant ER/Sp1-‘‘XRE’’-tk-CAT plasmid; however, TCDD did
not inhibit the hormone-induced response. These data also
demonstrate that the plasmid-containing mutants with muta-
tions in the XRE are not responsive to the effects of TCDD.
Electrophoretic mobility shift assays of nuclear extracts,
transformed cytosol from MCF-7 cells, and in vitro-translated
proteins using wild-type and mutant ER/Sp1 oligonucleotides.
The results in Fig. 4 illustrate the pattern of retarded bands in
electrophoretic mobility shift assays using the wild-type ER/
Sp1 and the mutant ER/Sp1-‘‘XRE’’ oligonucleotides in a ti-
tration experiment using TCDD (20 nM)- or DMSO-trans-
formed cytosol from MCF-7 cells as previously reported (51).
Incubation of wild-type [32P]ER/Sp1 oligonucleotide (Fig. 4)
with nuclear extracts fromMCF-7 cells treated with DMSO, 10
nM E2, 10 nM TCDD alone, or 10 nM E2 (24 h) plus 10 nM
TCDD for 1 h showed that relatively low levels of ER/Sp1
binding were observed in cells treated with DMSO and TCDD
whereas E2 induced ER/Sp1 binding and TCDD rapidly inhib-
ited the E2-induced response. In cells cotreated with E2,
TCDD, and 1 mM aNF, the effects of TCDD on formation of
FIG. 1. RIA of immunoreactive cathepsin D (cath-D) using cytosolic cathep-
sin D levels (top) and cathepsin D mRNA levels (bottom) in MCF-7 cells. Levels
of immunoreactive cathepsin D (A) were determined after treatment of cells
with 1 nM E2 alone for 24 h and after treatment with 1 nM TCDD alone (F) for
2, 4, 6, and 12 h. The effect of cotreatment on immunoreactive cathepsin D was
determined in cells treated with 1 nM E2 for 24 h and TCDD for 1, 2, 4, 6, and
12 h (h). The amount of immunoreactive cathepsin D in control cells was
determined after treatment with DMSO (vehicle control) for 24 h and was
assigned a value of 100%. The amount of protein in femtomoles per milligram
was determined by plotting a standard curve as indicated in the instructions for
the RIA kit. The results are expressed as means 6 SD for at least three deter-
minations for each time point. E2 significantly induced cathepsin D levels at all
time points (P , 0.05), and TCDD significantly inhibited the E2-induced re-
sponse at all time points (P , 0.05). Cathepsin D mRNA levels (B) were
determined in cells treated with 1 nM E2 alone for 24 h and with 10 nM TCDD
alone (F) for 1, 2, 4, 8, and 12 h. Cathepsin D mRNA levels were also deter-
mined in MCF-7 cells cotreated with 10 nM E2 for 24 h plus 10 nM TCDD (h)
for 1, 2, 4, 8, and 12 h. Treatment of cells with DMSO for 24 h gave control
cathepsin D mRNA levels, which were assigned a value of 100%. Cathepsin D
mRNA was isolated, visualized by Northern blot analysis, and quantitated by a
Betagen Betascope 603 blot analyzer as described in Materials and Methods.
Cathepsin D mRNA levels were normalized relative to b-tubulin mRNA for
each treatment group.
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the ER/Sp1 retarded band were reversed (data not shown).
Coincubation of nuclear extracts from E2-induced MCF-7 cells
with cytosol from MCF-7 cells transformed with DMSO re-
sulted in minimal effects on ER/Sp1 binding, whereas coincu-
bation with cytosol transformed with 20 nM TCDD resulted in
a significant loss of ER/Sp1 binding. The same experiment was
repeated with the mutated ER/Sp1-‘‘XRE’’ oligonucleotide
(Fig. 4), and the binding of nuclear extracts from E2-treated
cells was not decreased after coincubation with DMSO- or
TCDD-transformed cytosol; the intensities of the retarded
ER-Sp1 complex were comparable after the mutant ER/Sp1-
‘‘XRE’’ was incubated with nuclear extracts from MCF-7 cells
treated with 10 nM E2 or 10 nM E2 plus 10 nM TCDD for 1
h. These results demonstrate that the transformed or nuclear
Ah receptor complexes blocked formation of the ER-Sp1 com-
plex and this inhibitory response was dependent on an intact
XRE sequence.
Figure 5A illustrates the results of SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) of nuclear extracts from MCF-7
cells cross-linked to a BrdU-ER/Sp1 oligonucleotide. Nuclear
extracts from DMSO-treated cells did not form a cross-linked
band (lane 2); incubation of nuclear extracts from cells treated
with 10 nM TCDD plus 10 nM E2 and [32P]BrdU-ER/Sp1 gave
a 200-kDa cross-linked band (lane 3), and coincubation with a
100-fold excess of unlabeled DRE (lane 4) resulted in de-
creased formation of this band. Competition with a mutated
DRE oligonucleotide (lane 5) did not decrease the intensity of
the cross-linked band. Only weak, specifically bound cross-
linked bands were observed with extracts from cells treated
with 10 nM E2 or 10 nM TCDD alone (data not shown). In
parallel experiments, cells were treated with 10 nM E2 and 10
nM [3H]TCDD in the presence or absence of a 200-fold excess
of unlabeled TCDF. After cross-linking and photoaffinity la-
beling followed by SDS-PAGE, the gels were sliced, and the
specifically-bound radioactivity (3H) was localized in the 200-
kDa cross-linked band (Fig. 5B).
The binding of the Ah receptor complex to the ER/Sp1
oligonucleotide was further investigated with an Ah receptor
complex formed by reconstituting the Ah receptor and Arnt
proteins expressed in vitro by using the rabbit reticulocyte
lysate system (Fig. 6). Direct binding of the reconstituted Ah
receptor complex to [32P]ER/Sp1 was not detected (data not
FIG. 2. Effect of 10 nM TCDD on the rate of E2-mediated cathepsin D (CATH-D) gene expression. (A) MCF-7 cells were treated with DMSO (control), 10 nM
E2 (24 h), 10 nM TCDD (30 min) plus 10 nM E2, or 10 nM TCDD (1 h) plus 10 nM E2. Cotreated cells were treated with E2 for 24 h, and TCDD was added 30 min
or 1 h prior to the end of this period. Cells in the various treatment groups were harvested at appropriate times, and nuclei were obtained and subjected to the nuclear
run-on assay as described in Materials and Methods. The amount of newly transcribed mRNA was quantitated by slot blot analysis using a scanning laser densitometer.
(B) Cathepsin D mRNA levels were normalized relative to b-tubulin in mRNA and expressed as means 6 SD for three separate determinations. Cathepsin D mRNA
levels in the different treatment groups were compared with levels in control cells, which were assigned a value of 100%. E2 significantly induced cathepsin D gene
transcription after treatment for 6 h; TCDD significantly inhibited the E2-induced response within 30 [TE(30)] or 60 [TE(60)] min after addition (P , 0.05). (C) RNA
was isolated from MCF-7 cells treated with DMSO (lane 1), 10 nM E2 alone for 24 h (lane 2), or 10 nM E2 for 24 h plus 10 nM TCDD for 1 h (lane 3). The Northern
blot was visualized by autoradiography and quantitated by a Betagen Betascope blot analyzer as described for Fig. 1. Cathepsin D mRNA levels were normalized to
b-tubulin mRNA for each treatment group, and the relative cathepsin D mRNA levels were 100 6 12 (lane 1), 301 5 60 (lane 2), and 158 6 16 (lane 3). The levels
in cells treated with 10 nM TCDD alone were 156 6 14 (data not shown). The results are expressed as means 6 SD for three separate determinations. There was a
significant decrease (P , 0.05) in cathepsin D mRNA levels in the cotreated cells compared with those treated with E2 alone.
TABLE 1. Inhibition of E2-induced alkaline phosphatase activity
by TCDD in MCF-7 and Hepa 1c1c7 cells transfected
with the Seap-pac and hER plasmidsa
Treatment (h)
Alkaline phosphatase activity (% of control)
MCF-7 Wild-typeHepa 1c1c7
Class II
mutants
DMSO (48) 100 6 1 100 6 9 100 6 14
E2 (48) 845 6 89 690 6 30 640 6 100
E2 (48) 1 TCDD (1) 782 6 87
E2 (48) 1 TCDD (2) 629 6 30b 435 6 51b 501 6 70
E2 (48) 1 TCDD (4) 515 6 47b
E2 (48) 1 TCDD (6) 311 6 30b 316 6 38b 657 6 47
E2 (48) 1 TCDD (12) 245 6 28b 268 6 9b 595 6 72
E2 (48) 1 TCDD (24) 153 6 13b 115 6 16b 601 6 99
S1c 53 6 13 37 6 3 22 6 14
RSVd 1,533 6 240 1,250 6 17 860 6 72
a Cells were treated with 10 nM E2 alone for 48 h, and, in the cotreatment
group, cells were treated with 10 nM E2 for 48 h and 10 nM TCDD was added
at different time points prior to the end of the 48-h period. The cells were
cotransfected with the Seap-pac and hER plasmids, and secreted alkaline phos-
phatase activity was determined as described in Materials and Methods. Treat-
ment of cells with 10 nM TCDD alone for 12 h and the Seap-pac plasmid did not
result in increased alkaline phosphatase activity compared with DMSO treat-
ment; however, in cells transfected with the hER and Seap-pac plasmids and
treated with 10 nM TCDD, there was a significant increase in alkaline phos-
phatase activity in MCF-7, wild-type, and mutant Hepa 1c1c7 cells (data not
shown). The Ah receptor-independent responses were not further investigated.
b Significantly lower (P , 0.05) than the value for cells treated with E2 alone.
c Negative control.
d Positive control.
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shown), but a specifically bound complex was formed after
incubation with [32P]DRE (lane 1). The intensity of this re-
tarded band was not decreased after coincubation with a 100-
fold excess of ERE (lane 3), 100- or 400-fold excess of ER/
Sp1-‘‘XRE’’ (lanes 6 and 7), or 100-fold excess of mutated
DRE (data not shown). In contrast, competition with 100-fold
excess DRE (lane 2) or 100- or 400-fold excess of ER/Sp1
(lanes 4 and 5) decreased formation of the specifically bound
DRE-Ah receptor complex retarded band. These results with
in vitro-expressed Ah receptor and Arnt proteins confirm the
interaction of the Ah receptor-Arnt heterodimer with the XRE
sequence located within the cathepsin D ER/Sp1 oligonucleo-
tide.
DISCUSSION
Several studies report that TCDD and related compounds
inhibit a number of E2-induced responses (2, 3, 22–25, 30, 32,
38, 40, 66, 84a, 85) including secretion of procathepsin D and
cathepsin D in MCF-7 cells. Studies using wild-type Ah-re-
sponsive and mutant Ah-nonresponsive MCF-7 cells showed
that formation of a transcriptionally active nuclear Ah receptor
was required for inhibition of E2-induced secretion of pro-
cathepsin D by TCDD (51). Moreover, there was a good cor-
relation between the structure-Ah receptor binding affinities
for several Ah receptor agonists and their structure-dependent
inhibition of this E2-induced secretory protein (40). This study
further investigates the molecular mechanism of action of
FIG. 3. Effects of TCDD, aNF, and antisense Arnt on E2-induced ER/Sp1-
tk-CAT activity: requirement for a functional nuclear Ah receptor-Arnt complex
and intact XRE sequence. MCF-7 cells were transiently transfected as described
in Materials and Methods. Briefly, cells were seeded in DME-F12 media con-
taining fetal bovine serum stripped twice, and were grown to 60% confluency.
ER/Sp1-tk-CAT plasmids (10 mg) along with the hER plasmid (5 mg) or Arnt
antisense plasmid (10 mg) were mixed in a solution containing Polybrene and
added to the media. Cells were shocked after 12 h by using 15% glycerol in
Hanks solution and dosed with DMSO (C), 10 nM E2, 10 nM TCDD plus 10 nM
E2 (TE), 10 nM TCDD alone (T), 10 nM E2 plus 1 mM a-NF (aE), or 10 nM
TCDD plus 10 nM E2 plus 1 mM a-NF (aET). After 48 h, cells were harvested
and assayed for CAT (Acet.) activity. CAT activities relative to that for the
control (lane 1, 100% 6 9%) were as follows: lane 2, 364 6 29; lane 3, 102 6 14;
lane 4, 95 6 12; lane 5, 372 6 40; lane 6, 375 6 35; lane 7, 100 6 14; lane 8, 405
6 28; lane 9, 325 6 30; lane 10, 132 6 12. Lanes 7 through 10, cells transfected
with both the wild-type ER/Sp1-tk-CAT plasmid and the antisense Arnt expres-
sion plasmid. In a separate experiment, the mutant ER/Sp1-‘‘XRE’’-tk-CAT
plasmid was utilized as described above, and relative CAT activities in cells
treated with DMSO (assigned a value of 100%), E2, TCDD plus E2, and TCDD
alone were 100 6 14, 298 6 30, 302 6 42, and 95 6 14, respectively (lanes 11
through 14). CAT activities in experiments using antisense Arnt DNA or 1 mM
aNF were not significantly different from control values (data not shown). Re-
sults are expressed as means 6 SD for three separate experiments.
FIG. 4. Effect of TCDD on ER/Sp1 binding: role of the XRE. Nuclear
extracts from MCF-7 cells treated with DMSO (lanes C), 10 nM E2 alone for 24
h (lanes E), 10 nM TCDD for 1 h plus 10 nM E2 for 24 h (lanes TE1), or 10 nM
TCDD alone for 1 h (lanes T) were isolated, incubated with the mutant [32P]ER/
Sp1-‘‘XRE’’ or wild-type [32P]ER/Sp1 oligonucleotide, and analyzed by electro-
phoretic mobility shift assays as described in Materials and Methods. Cytosolic
extracts were obtained from MCF-7 cells and transformed in vitro with 20 nM
TCDD or DMSO for 2 h at 258C as previously described (51). Cytosol (100 ml)
transformed with TCDD (lanes TE) or DMSO (lanes DE) was incubated with
nuclear extracts from E2-treated cells plus [32P]ER/Sp1 or mutant [32P]ER/Sp1
oligonucleotide and analyzed by electrophoretic mobility shift assay. The re-
tarded ER/Sp1 bands (arrow) were visualized by autoradiography and quanti-
tated by a Molecular Dynamics 300A laser densitometer. The intensity values in
lanes 2 through 12 relative to the control band (lane 1, 100% 6 15%) were 510
6 42, 525 6 30, 470 6 22, 440 6 35, 50 6 7, 90 6 9, 444 6 42, 65 6 17, 330 6
23, 95 6 11, and 80 6 10 (means 6 SD for three separate determinations),
respectively. The intensities of the ER-Sp1 complexes in lanes 6, 7, 9, 11, and 12
were all significantly lower (P , 0.05) than that observed for complexes with
extracts from E2-treated cells and the mutant (lane 2) or wild-type (lane 8)
ER/Sp1 oligonucleotide. Previous studies have determined the binding specificity
of the ER/Sp1 band (41).
TABLE 2. Inhibition of E2-induced CAT mRNA levels by TCDD
in MCF-7 cells transiently cotransfected with the hER and
ER/Sp1-tk-CAT or ER/Sp1-‘‘XRE’’-tk-CAT plasmidsa
Treatment (h)
Relative % CAT mRNA
ER/Sp1-tk-CAT ER/Sp1-‘‘XRE’’-tk-CAT
DMSO 100 6 20 100 6 15
E2 (10) 278 6 30 327 6 21
TCDD (2) 120 6 12 114 6 15
E2 (10) 1 TCDD (2) 95 6 19b 348 6 31
a Cells were cotransfected with the hER and ER/Sp1-tk-CAT or mutant ER/
Sp1-‘‘XRE’’-tk-CAT plasmids and treated with 10 nM E2 for 10 h and 10 nM
TCDD for 2 h prior to the end of the 10-h incubation period as described in
Materials and Methods. CAT mRNA levels were determined by Northern blot
analysis (standardized relative to b-tubulin mRNA), and the relative CAT
mRNA levels are given as means 6 SD for three separate determinations.
b Significantly lower (P , 0.05) than the value for cells treated with E2 alone.
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TCDD as an antiestrogen and utilizes the E2-responsive ca-
thepsin D gene as a model.
The results summarized in Fig. 1 and 2 demonstrate that E2
induced intracellular immunoreactive cathepsin D levels, ca-
thepsin D mRNA levels, and the rate of cathepsin D gene
transcription in nuclear run-on assays. In cells cotreated with
E2 plus TCDD, all of the induced responses were significantly
inhibited within 0.2 to 2 h after treatment with TCDD, sug-
gesting that TCDD induces an early gene product which affects
cathepsin D gene transcription at some level or there is a direct
interaction of the nuclear Ah receptor complex with protein
and/or DNA elements involved in transactivation of this gene.
Deletion analysis of the 59-flanking region of the cathepsin
D gene identified several nonconsensus ERE sequences and an
E2-responsive region from 2252 to 2124 (4). The Seap-pac
plasmid containing the 2296/159 59-flanking sequence from
the cathepsin D gene (63) was used to determine the effects of
TCDD on E2-induced secreted alkaline phosphatase activity in
cells transiently transfected with this plasmid (Table 1). In
Ah-responsive human MCF-7 and wild-type mouse Hepa
1c1c7 cells transiently transfected with the Seap-pac and hER
plasmids, E2 induces secreted alkaline phosphatase activity
and TCDD inhibited the induced response within 2 h after
treatment. In contrast, TCDD did not inhibit E2-induced al-
kaline phosphatase activity in the class II mutant Hepa 1c1c7
cell line, which expresses the Ah receptor but does not form
transcriptionally active nuclear Ah receptor complexes (50).
These results confirm that the antiestrogenic response requires
a functional nuclear Ah receptor complex and genomic se-
quences within the 2296/159 region are sufficient for mediat-
ing the TCDD-induced inhibitory response.
Results of previous studies suggest that formation of ER-
Sp1 complexes regulates E2-induced transactivation of the c-
myc, creatine kinase B, and cathepsin D genes (18, 41, 84). An
ER-Sp1 complex, GGGCGGn23ACGGG, was previously iden-
tified (2199 to 2165) in the cathepsin D promoter (41), and
further analysis of this sequence has identified an XRE, namely
FIG. 5. Cross-linking of the nuclear Ah receptor complex with BrdU-ER/Sp1. (A) The BrdU-ER/Sp1 oligonucleotide was incubated with nuclear extracts from cells
treated with DMSO (control [CTL]) (lane 2), TCDD plus E2 (TE) (lane 3), or TCDD plus E2 in the presence of 100-fold excess of unlabeled wild-type DRE (lane
4) or mutant (Mut) DRE (lane 5). Incubation, cross-linking, and electrophoresis of the cross-linked complexes were carried out as described in Materials and Methods.
The 200-kDa cross-linked (X-linked) Ah receptor complexes (arrow) were visualized by autoradiography and quantitated by using a Sharp SX-330 scanner and
Scanalytics (Billerica, Mass.) ZERO-Dscan software. Molecular weights were determined with 14C-labeled protein standards purchased from Amersham Corp. (lane
1). The band intensity values in lanes 3 to 5 relative to the control (lane 2, 100% 6 37%) were 404 6 14, 121 6 2, and 346 6 5, respectively; the results are means
6 SD for three determinations. CATD, cathepsin D. (B) Nuclear extracts were obtained as described in Materials and Methods from MCF-7 cells treated with 10 nM
[3H]TCDD plus 10 nM E2 alone or in combination with a 200-fold excess of TCDF. Incubation, cross-linking, and electrophoresis were carried out, and the regions
corresponding to the cross-linked complex were excised for the two treatment groups, extracted with Solvable (Dupont), and counted in a liquid scintillation counter.
The values obtained were 15,140 dpm ([3H]TCDD plus E2) and 1,442 dpm ([3H]TCDD plus E2 plus TCDF). Background levels (520 dpm) were subtracted to give
the net dpm values for the 200-kDa band. The only radioactive (3H) band on the gel was associated with the photoaffinity-labeled 200-kDa cross-linked band.
FIG. 6. Electrophoretic mobility shift assays using in vitro-translated Ah re-
ceptor and Arnt. In vitro-translated proteins were obtained as described in
Materials and Methods. Ah receptor (3 ml) and Arnt (3 ml) or unprogrammed
rabbit reticulocyte lysate (UPL) (6 ml) were incubated in the presence of 20 nM
TCDD for 2 h at 258C. The preincubated proteins were then subjected to gel
electrophoretic mobility shift assay using a 32P-labeled DRE oligonucleotide.
The retarded band (lane 1) (arrow) was blocked with a 100-fold excess of an
unlabeled DRE oligonucleotide (lane 2), 100-fold excess of an unlabeled ERE
oligonucleotide (lane 3), 100- or 400-fold excess of an unlabeled ER/Sp1 (wild-
type cathepsin D [WT CATD]) oligonucleotide (lanes 4 and 5), or 100- or 400-
fold excess of an unlabeled ER/Sp1-‘‘XRE’’ (‘‘XRE’’ CATD) oligonucleotide (lanes
6 and 7). In the absence of ligand, a specifically bound, but less intense, retarded
band (20 to 25% the intensity of the band in lane 1) was observed (data not shown).
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GTGCGTG (2175/2181), located between the genomic se-
quences which bind the ER and Sp1 proteins. The potential
role of this XRE as a critical target site for mediating the
antiestrogenic effects of TCDD was therefore investigated by
utilizing the wild-type ER/Sp1 and a mutant ER/Sp1-‘‘XRE’’
oligonucleotide in electrophoretic mobility shift assays and in
transient transfection assays in which these oligonucleotides
were cloned into plasmids with a thymidine kinase promoter
and a CAT reporter gene. The results in Fig. 4 illustrate that
nuclear extracts from MCF-7 cells treated with 10 nM E2
formed a retarded ER-Sp1 complex with both wild-type ER/
Sp1 (lane 8) and mutant ER/Sp1-‘‘XRE’’ (lane 2) oligonucle-
otides. Electrophoretic mobility shift assays of nuclear extracts
from cells treated with 10 nM E2 (24 h) plus 10 nM TCDD for
1 h showed that TCDD blocked formation of a retarded band
with the wild-type ER/Sp1 (Fig. 4, lane 12) but not the mutant
ER/Sp1-‘‘XRE’’ (Fig. 4, lane 5) oligonucleotide. The role of the
Ah receptor heterodimer in destabilizing formation of the ER-
Sp1 complex was further investigated by incubating nuclear
extracts from E2-treated MCF-7 cells with cytosolic extracts
treated with DMSO or 20 nM TCDD, which transforms the
cytosolic Ah receptor to an XRE-binding form indistinguish-
able from the nuclear Ah receptor complex (51). The trans-
formed cytosolic Ah receptor decreased formation of the ER-
Sp1 complex (Fig. 4, lane 11), whereas formation of the ER-
Sp1 complex was not affected by addition of transformed Ah
receptor complex using the mutant ER/Sp1-‘‘XRE’’ oligonu-
cleotide (Fig. 4, lane 4). Thus, disruption of the ER-Sp1 com-
plex requires (i) the intact XRE sequence located between the
ER and Sp1 genomic binding sites in the cathepsin D promoter
and (ii) the presence of transformed or nuclear Ah receptor
complex (T and TE1 lanes, respectively, with the ER/Sp1 oligo-
nucleotide; Fig. 4).
The results of the gel electrophoretic mobility shift assays
did not show a retarded band associated with direct binding of
the transformed or nuclear Ah receptor complex with the wild-
type ER/Sp1 oligonucleotide (Fig. 4). This may be due to
increased protein-DNA dissociation which can result in loss of
a retarded band in the assay system. Therefore, two additional
experiments were performed to investigate binding of the Ah
receptor complex to the DRE located within the ER/Sp1 oli-
gonucleotide (Fig. 5 and 6). Cross-linking experiments with the
BrdU-ER/Sp1 oligonucleotide showed that a specifically bound
TCDD-induced 200-kDa cross-linked complex was formed only
with nuclear extracts from MCF-7 cells treated with E2 plus
TCDD (Fig. 5A, lane 3). Competition with excess unlabeled
DRE oligonucleotide decreased formation of the cross-linked
band (lane 4), whereas competition with mutant DRE had
minimal effect (lane 5). In this study, only one major specifi-
cally bound cross-linked 200-kDa band was observed, and this
was consistent with results obtained with MCF-7 and T47D
breast cancer cells (78). Previous studies have demonstrated
that UV irradiation of the nuclear Ah receptor complex bound
with [3H]TCDD results in photoaffinity labeling of the Ah
receptor (77). In parallel cross-linking experiments using the
BrdU-ER/Sp1 oligonucleotide and nuclear extracts from cells
treated with [3H]TCDD plus E2, the specifically bound radio-
activity (3H) was localized in the 200-kDa band (Fig. 5B).
Thus, formation of the cross-linked complex (Fig. 5A) was
induced by TCDD only in cells cotreated with E2, suggesting
that E2-induced formation of the ER-Sp1 complex is required
to facilitate accessibility and interaction of the Ah receptor
complex with the XRE site; these data are consistent with
results showing that disruption of the retarded ER-Sp1 band
(Fig. 4) by the nuclear Ah receptor complex required an intact
XRE and occurred only in extracts from cells cotreated with
TCDD plus E2.
The data in Fig. 6 also confirm competitive binding of the
reconstituted Ah receptor-Arnt heterodimer with in vitro-
translated proteins. Unlabeled DRE (lane 2) and unlabeled
ER/Sp1 (lanes 4 and 5) oligonucleotides competitively de-
crease formation of the retarded [32P]DRE-Ah receptor com-
plex. In contrast, competition with the ER/Sp1-‘‘XRE’’ oligo-
nucleotide (lanes 6 and 7), which contains mutations in the
XRE sequence, does not decrease formation of the retarded
band. Thus, in competitive binding studies, wild-type ER/Sp1
competitively decreased formation of the DRE-Ah receptor
complex retarded band, confirming the competitive binding
affinity of the ER/Sp1 oligonucleotide with the Ah receptor/
Arnt heterodimer.
The results obtained in transient transfection studies using
the wild-type ER/Sp1-tk-CAT and mutant ER/Sp1-‘‘XRE’’-tk-
CAT plasmids (Fig. 3) complement the results of electro-
phoretic mobility shift assays and confirm that the antiestro-
genic activity of TCDD requires a nuclear Ah receptor
complex and an intact XRE sequence within the ER/Sp1 oli-
gonucleotide. TCDD inhibited E2-induced CAT activity and
mRNA levels (Table 2) in MCF-7 cells transiently transfected
with the ER/Sp1-tk-CAT construct (Fig. 3, lane 3), whereas no
inhibition of CAT activity or mRNA levels was observed with
the mutant ER/Sp1-‘‘XRE’’-tk-CAT construct (Fig. 3, lane 13)
containing C3A mutations in the XRE (antisense strand). In
addition, aNF, an Ah receptor antagonist which inhibits for-
mation of the nuclear Ah receptor complex (49) (Fig. 3, lane 5)
and expression of antisense Arnt mRNA (Fig. 3, lane 9),
blocked the antiestrogenic activity of TCDD.
In summary, the results of in vitro binding and induction
assays using wild-type and mutated 59-flanking ER/Sp1 se-
quences indicate that the core XRE sequence located between
the ER and Sp1 genomic binding sites in the cathepsin D
promoter is required for disruption of the E2-induced ER-Sp1
complex by TCDD. These data demonstrate a unique Ah re-
ceptor-mediated mechanism of action in which direct interac-
tion of the nuclear Ah receptor complex with a strategically
located XRE results in decreased transcription of an E2-in-
duced gene. Binding to an XRE sequence may also be impor-
tant for inhibition of E2-induced pS2 gene expression by
TCDD (84a), and it is possible that similar mechanisms may
play a role in cell-specific inhibition of other genes by Ah
receptor agonists (82). The mechanisms associated with inhi-
bition of other E2- and mitogen-induced genes by TCDD in
breast cancer cell lines are unknown and are currently being
investigated in this laboratory.
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